Cilostazol and primary-PCI: mirage or good alternative?

Italo Porto, Domenico D'Amario, Filippo Crea

Risultato della ricerca: Contributo in rivistaArticolo in rivista

4 Citazioni (Scopus)


Oral anti-platelet agents targeting the platelet P2Y12 receptor are an integral component of treating patients undergoing percutaneous coronary interventions. Advancements in the design of stents and catheters are pushing the technique towards treatment of high risk lesions whose failure would expose patients to catastrophic events. Success of these complex procedures largely lays on efficacy of anti-platelet drugs and the limitation of stent restenosis and/or thrombosis. Clopidogrel has been the most commonly used agent in this respect worldwide. However, there are certain shortcomings of clopidogrel, the most important of which is the wide response variability of platelet inhibition. Thus, clinicians are facing challenges in treating patients where high inhibition of platelets is necessary and the response to clopidogrel may be insufficient. In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis. Therefore, cilostazol may be considered, on top of our current anti-platelet therapy, as a potential candidate to achieve optimal platelet inhibition especially in patients undergoing primary-PCI (p-PCI) or high risk procedures. This review will focus on the pharmacological characteristics of cilostazol and the initial evidences that support the use of this drug in the setting of p-PCI.
Lingua originaleEnglish
pagine (da-a)468-471
Numero di pagine4
RivistaCurrent Vascular Pharmacology
Stato di pubblicazionePubblicato - 2012


  • Acute Coronary Syndrome
  • Angioplasty, Balloon, Coronary
  • Arrhythmias, Cardiac
  • Aspirin
  • Combined Modality Therapy
  • Coronary Restenosis
  • Drug Therapy, Combination
  • Heart Failure
  • Humans
  • Phosphodiesterase 3 Inhibitors
  • Platelet Aggregation Inhibitors
  • Prodrugs
  • Risk
  • Stents
  • Tetrazoles
  • Thrombosis
  • Ticlopidine


Entra nei temi di ricerca di 'Cilostazol and primary-PCI: mirage or good alternative?'. Insieme formano una fingerprint unica.

Cita questo